Primary biliary cirrhosis medical therapy: Difference between revisions
Jump to navigation
Jump to search
Line 18: | Line 18: | ||
** 1.1 Preferred regimen : [[Ursodeoxycholic acid|Ursodeoxycholic acid (UDCA)]] 13-15 mg PO q12h for 10-21 days '''(Contraindications/specific instructions)''' | ** 1.1 Preferred regimen : [[Ursodeoxycholic acid|Ursodeoxycholic acid (UDCA)]] 13-15 mg PO q12h for 10-21 days '''(Contraindications/specific instructions)''' | ||
* '''2''' ''' | * '''2''' '''Immunomodulator''' | ||
** 2.1 '''[[Glucocorticoid]] ''' | ** 2.1 '''[[Glucocorticoid]] ''' | ||
*** Preferred regimen : [[Budesonide]] 6 to 9 mg per day PO '''contraindicated for patients who have hypersensitivity to budesonide''' | *** Preferred regimen : [[Budesonide]] 6 to 9 mg per day PO '''(contraindicated for patients who have hypersensitivity to budesonide)''' | ||
*** Cyclosporine: Preferred regimen :5-10 mg PO q24h | |||
*** 2.2 [[Folate antagonist]] | |||
* '''3''' '''Farnesoid-X-receptor (FXR) agonist''' | * '''3''' '''Farnesoid-X-receptor (FXR) agonist''' | ||
** 3.1 Obetocholic acid | **3.1 Obetocholic acid | ||
* | *'''4''' '''Peroxisome proliferator-activated receptor agonist ''' | ||
** Fibrates | |||
** | |||
==References== | ==References== |
Revision as of 19:19, 5 February 2018
Primary Biliary Cirrhosis Microchapters |
Differentiating Primary Biliary Cirrhosis from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Primary biliary cirrhosis medical therapy On the Web |
American Roentgen Ray Society Images of Primary biliary cirrhosis medical therapy |
Risk calculators and risk factors for Primary biliary cirrhosis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Pharmacologic medical therapies for Primary biliary cirrhosis include Immunomodulators,antifibrotics and anticholestatics. The anticholestatic Ursodeoxycholic acid (UDCA) is recommended as the first line medical therapy for PBC.
Medical Therapy
- Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].
- Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].
- Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].
- Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].
Primary biliary cirrhosis
- 1 Anticholestatics
- 1.1 Preferred regimen : Ursodeoxycholic acid (UDCA) 13-15 mg PO q12h for 10-21 days (Contraindications/specific instructions)
- 2 Immunomodulator
- 2.1 Glucocorticoid
- Preferred regimen : Budesonide 6 to 9 mg per day PO (contraindicated for patients who have hypersensitivity to budesonide)
- Cyclosporine: Preferred regimen :5-10 mg PO q24h
- 2.2 Folate antagonist
- 2.1 Glucocorticoid
- 3 Farnesoid-X-receptor (FXR) agonist
- 3.1 Obetocholic acid
- 4 Peroxisome proliferator-activated receptor agonist
- Fibrates